JP2009215293A5 - - Google Patents

Download PDF

Info

Publication number
JP2009215293A5
JP2009215293A5 JP2009052853A JP2009052853A JP2009215293A5 JP 2009215293 A5 JP2009215293 A5 JP 2009215293A5 JP 2009052853 A JP2009052853 A JP 2009052853A JP 2009052853 A JP2009052853 A JP 2009052853A JP 2009215293 A5 JP2009215293 A5 JP 2009215293A5
Authority
JP
Japan
Prior art keywords
ziprasidone
dosage form
oral dosage
solid oral
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009052853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009215293A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009215293A publication Critical patent/JP2009215293A/ja
Publication of JP2009215293A5 publication Critical patent/JP2009215293A5/ja
Withdrawn legal-status Critical Current

Links

JP2009052853A 2008-03-07 2009-03-06 食物なしでジプラシドンを投与するための方法、剤形、およびキット Withdrawn JP2009215293A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07

Publications (2)

Publication Number Publication Date
JP2009215293A JP2009215293A (ja) 2009-09-24
JP2009215293A5 true JP2009215293A5 (https=) 2012-04-12

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009052853A Withdrawn JP2009215293A (ja) 2008-03-07 2009-03-06 食物なしでジプラシドンを投与するための方法、剤形、およびキット

Country Status (15)

Country Link
US (1) US20110002989A1 (https=)
EP (1) EP2280711A1 (https=)
JP (1) JP2009215293A (https=)
KR (1) KR20100131477A (https=)
CN (1) CN102014910A (https=)
AR (1) AR070964A1 (https=)
AU (1) AU2009220925A1 (https=)
BR (1) BRPI0909818A2 (https=)
CA (1) CA2719115A1 (https=)
IL (1) IL207792A0 (https=)
MX (1) MX2010009844A (https=)
RU (1) RU2010135831A (https=)
TW (1) TW200950783A (https=)
WO (1) WO2009109844A1 (https=)
ZA (1) ZA201005905B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
KR102337598B1 (ko) * 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
PE20160605A1 (es) 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Syk 억제제의 다형체
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
WO2016044703A1 (en) * 2014-09-19 2016-03-24 The Procter & Gamble Company Process for making a core with an active coating
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Similar Documents

Publication Publication Date Title
JP2009215293A5 (https=)
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
JP2014528474A5 (https=)
JP2017128614A5 (https=)
RU2019134558A (ru) Композиции и способы лечения анемии
JP2019507797A5 (https=)
CN103096878B (zh) 包含苯并咪唑衍生物的固体药物组合物
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
JP2018505158A5 (https=)
JP2020530831A5 (https=)
JP2015515984A5 (https=)
JP2016507500A5 (https=)
JP2020500864A5 (https=)
JP2019534330A5 (https=)
JP2014533701A5 (https=)
JP2007500176A5 (https=)
EP3856177A1 (en) Grapiprant unit dosage forms
JP2016512247A5 (https=)
KR20160011205A (ko) 히드로코티손을 포함하는 조성물
CN102485228A (zh) 一种药物组合物及其用途
CN105106243A (zh) Bacteroides thetaiotaomicron VPI-5482在制备治疗或预防肥胖症药物中的应用
JP2010529125A5 (https=)
CN106038566B (zh) 一种用于胃癌治疗的药物组合物及其应用
JP2016504390A5 (https=)
Yanev et al. Pain in obesity is not obesity and pain